L’Oréal strengthens its Luxe portfolio with the acquisition of science-led professional skincare brand Medik8. The move aims at global growth and continued innovation in premium dermatological beauty.
L’Oréal Groupe has announced that it will acquire a majority stake in British skincare brand Medik8 by scientist Elliot Isaacs. Medik8 is famous for its Crystal Retinal serum and its CSA Philosophy© — using Vitamin C and sunscreen by day and Vitamin A by night. The brand focuses on delivering visible skincare results through high-performance ingredients and science.
As part of the agreement, Inflexion, a European private equity firm, will stay on as a minority shareholder. Elliot Isaacs will continue to be on the board, and the current management team will remain to ensure smooth continuity.
A Boost to L’Oréal’s Luxe Portfolio
Medik8 started with professional skincare roots and now sells across major online and offline retailers in Europe. It is also expanding its presence in the United States. The acquisition will allow L’Oréal to consolidate Medik8’s sales after the deal closes. It is likely happening in the coming months, pending regulatory approvals.
L’Oréal has also secured the option to fully buy out minority shareholders in the future. This move further strengthens L’Oréal’s Luxe division with a strong, science-backed brand poised for global growth.
From the leadership desk
Cyril Chapuy, President of L’Oréal LUXE:
“We are delighted to welcome Medik8 to the L’Oréal family. As a premium skincare range, with high levels of proven efficacy at an accessible price point, Medik8 perfectly complements our existing skincare portfolio. We share a strong belief in Medik8’s global potential and are excited to embark on this journey together, to build a powerful and impactful brand presence worldwide.”
Simon Coble, CEO of Medik8:
“This is an exciting day for Medik8. I am delighted to be joining forces with a company which shares our vision for the brand’s future growth and whose core values align with our deep commitment to science, innovation and above all, results without compromise. I look forward to the next stage in Medik8’s journey, as we work together to bring our innovative products to a wider audience.”